ClinicalTrials.gg
CompletedNCT00902304VIPER-BPUpdated Dec 4, 2012Results posted

Valsartan Intensified Primary Care Reduction of Blood Pressure Study

A Phase 4 interventional study of Valsartan and hydrochlorothiazide (HCTZ) - monotherapy and Valsartan and amlodipine in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,337
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
5th of 139
2,337 · median 198
Started
2009
with 6 others
Phase 4
67 of 140
none open now
Registered
99th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 5th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2009, is one of 67 in phase 4, and was the 99th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • valsartan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner

Exclusion criteria

Exclusion Criteria:

  • significantly elevated blood pressure (severe hypertension)
  • requiring 3 or more antihypertensive drugs
  • severe kidney disease or dialyses
  • clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,337 participants (actual)

Study arms

  • Active comparator
    Usual care

    Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target

    Drug: Usual care

  • Experimental
    Monotherapy (initial monotherapy arm)

    Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.

    Drug: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy · Drug: Valsartan

  • Experimental
    Combination (initial combination therapy arm)

    Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.

    Drug: Valsartan and amlodipine · Drug: Valsartan and hydrochlorothiazide (HCTZ) - combination arm

Interventions

  • DrugValsartan and hydrochlorothiazide (HCTZ) - monotherapy

    Drug page: Hydrochlorothiazide

    Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally

  • DrugValsartan and amlodipine

    Drug pages: Valsartan · Amlodipine

    From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally

  • DrugUsual care

    As directed by investigator

  • Valsartan 160mg per day to 320mg per day orally

  • DrugValsartan and hydrochlorothiazide (HCTZ) - combination arm

    Drug page: Hydrochlorothiazide

    Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target

    BP target groups were: \<= 125/75mmHg, \<= 130/80mmHg and \<= 140/90mmHg. The BP target was based on the patient's clinical risk profile as specified by National Heart Foundation of Australia guidelines.

    Time frame: 26 weeks

Secondary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure

    The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.

    Time frame: Baseline and 26 weeks

  2. Change in Mean Sitting Diastolic Blood Pressure

    The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.

    Time frame: Baseline and 26 weeks

  3. Change in Absolute Cardiovascular Risk Score

    The absolute cardiovascular risk assessment uses the Framingham Risk Equation to predict risk of a cardiovascular event over the next 5 years. A score of \<10% is a low risk, 10 to 15% is a moderate risk, and \>15% is a high risk. A decrease indicates improvement.

    Time frame: Baseline and 26 weeks

  4. Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy

    The rate of all adverse events by preferred terms as determined by the General Practice investigators to be related to study intervention therapy was reported. Percentage of adverse events was calculated based on the number of participants analyzed. 41 adverse events were not reported as inadequate information was supplied to allow determination of drug treatment at onset.

    Time frame: 26 weeks

  5. Number of 'Early Responder' Patients Who Achieve Individualized Blood Pressure Control After 1 or 2 Adjustments

    A comparison of the early responders was made based on the blood pressure measurements taken at the week 6 visit window according to gender and guideline targets. The guideline targets were: patients with renal impairment: 125/75 mmHg; patients with end-organ damage/cardiovascular disease: 130/80 mmHg; others: 140/90 mmHg.

    Time frame: 26 weeks

  6. Change in the EQ-5D Score

    The EQ-5D total indexed score (AUS) measures self-reported quality of life with the following 5 dimensions: mobility (range 1,2,3), self-care (range 1,2,3), usual activity (range 1,2,3), pain/discomfort (range 1,2,3) and anxiety/depression (range 1,2,3), where a 1 indicates no problems, a 2 indicates moderate problems, and a 3 indicates severe problems. The range of possible utility scores are between -0.217 (derived from worse responses from all 5 dimensions with severe problems ie 3,3,3,3,3) and 1.000 (no problems for all 5 dimensions) for each dimension. An increase in EQ-5D indexed score (AUS) indicates improvement.

    Time frame: Baseline and 26 weeks

  7. Number of Patients With Depression

    Patients with depression refers to potential depressive symptoms, not clinically diagnosed depression. The 2 question Arrol screening tool was used to determine if the patient had potential depressive symptoms. The 2 questions are: During the last month have you often been bothered by feeling down, depressed or hopeless? During the past month have you often been bothered by little interest or pleasure in doing things? The presence of potential depressive symptoms was determined by a 'yes' answer to either of these questions.

    Time frame: Baseline and week 26

  8. Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26

    The CES-D score was from 0 to 30, with a higher score indicating a higher level of depression. The categories for the score are: 0 to 9 suggests no depression; 10 to 15 suggests mild depression; 16 to 24 suggests moderate depression; 24 or above suggests severe depression.

    Time frame: Baseline and week 26

  9. Participants With End Organ Disease at Baseline and Week 26

    A patient was considered to have end organ damage with either of the following: 1) proteinuria (dipstick = 1+ or more or protein/creatinine ratio \> 30mg/mol or 24h urine protein \> 0.3g); 2) no proteinuria, but presence of microalbuminuria (urine albumin/creatinine ratio 3.6 to 25mg/mol(male) or 3.6 to 35mg/mol (female) detected; 3) no proteinuria or microalbuminuria, but presence of macroalbuminuria (urine albumin/creatinine ratio \> 25mg/mol(male) or \>35mg/mol (female) detected OR 4) ECG evidence of LVH (Sokolow-Lyon voltage criteria values \>= 38mm). Baseline potential for end organ damage was calculated in all 1562 randomised patients based on the criteria outlined above. If no investigation/data available, assumed no end-organ damage. It is important to note that given the limited number of ECGs at 26 weeks, between group comparisons should be limited to the two time points (baseline and 26 weeks).

    Time frame: Baseline and week 26

  10. Change in Self-care Behavior Score From Baseline to Week 26

    A modified self-care behavior tool (questionnaire) was used to calculate 2 domain scales: maintenance and confidence. Each domain has a standardized score between 0 and 100. Self-care is best represented by maintenance. Confidence is an important process that moderates the relationship between self-care and outcomes. Higher index score suggests better self-care. A score of 70 or greater can be used as the cut-point to judge self-care adequacy.

    Time frame: Baseline and week 26

  11. Rate of Treatment Compliance

    The rate of compliance was planned to be estimated from the quantity of unused medication returned at each scheduled visit over the entire follow-up period. Rate of compliance = (tablets supplied - tablets returned)/(tablets for 100% compliance).

    Time frame: 26 weeks

  12. Number of Patients With Major Clinical Endpoints

    Major clinical endpoints measured were all-cause mortality and fatal and non-fatal cardiovascular events (e.g. acute myocardial infarction, stroke and heart failure).

    Time frame: 26 weeks

07

Results

Posted Aug 30, 2012

Participant flow

Participant flow — Overall Study
MilestoneUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Started524360678
Completed466289568
Not completed5871110
Withdrew: Adverse event41025
Withdrew: Investigator discretion3513
Withdrew: Lost to follow-up777
Withdrew: Protocol violation91820
Withdrew: Withdrawal by subject322243
Withdrew: Includes pregnancy392

Outcome measures

PrimaryPercentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target

BP target groups were: \<= 125/75mmHg, \<= 130/80mmHg and \<= 140/90mmHg. The BP target was based on the patient's clinical risk profile as specified by National Heart Foundation of Australia guidelines.

Time frame:
26 weeks
Reported as:
Number · percentage of participants
Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target
percentage of participantsUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target27.433.037.9
SecondaryChange in Mean Sitting Systolic Blood Pressure

The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.

Time frame:
Baseline and 26 weeks
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Systolic Blood Pressure
mmHgUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Change in Mean Sitting Systolic Blood Pressure-10 (-11.3 to -8.8)-11.6 (-13.1 to -10.0)-14.4 (-15.5 to -13.2)
SecondaryChange in Mean Sitting Diastolic Blood Pressure

The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.

Time frame:
Baseline and 26 weeks
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure
mmHgUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Change in Mean Sitting Diastolic Blood Pressure-5.45 (-6.2 to -4.7)-6.9 (-7.9 to -5.9)-8.29 (-9.0 to -7.6)
SecondaryChange in Absolute Cardiovascular Risk Score

The absolute cardiovascular risk assessment uses the Framingham Risk Equation to predict risk of a cardiovascular event over the next 5 years. A score of \<10% is a low risk, 10 to 15% is a moderate risk, and \>15% is a high risk. A decrease indicates improvement.

Time frame:
Baseline and 26 weeks
Reported as:
Mean · percentage risk score change
Change in Absolute Cardiovascular Risk Score
percentage risk score changeUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Change in Absolute Cardiovascular Risk Score-2.6 ± 4.5-3.3 ± 4.6-3.9 ± 4.5
SecondaryNumber of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy

The rate of all adverse events by preferred terms as determined by the General Practice investigators to be related to study intervention therapy was reported. Percentage of adverse events was calculated based on the number of participants analyzed. 41 adverse events were not reported as inadequate information was supplied to allow determination of drug treatment at onset.

Time frame:
26 weeks
Reported as:
Number · participants
Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy
participantsUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy7070169
SecondaryNumber of 'Early Responder' Patients Who Achieve Individualized Blood Pressure Control After 1 or 2 Adjustments

A comparison of the early responders was made based on the blood pressure measurements taken at the week 6 visit window according to gender and guideline targets. The guideline targets were: patients with renal impairment: 125/75 mmHg; patients with end-organ damage/cardiovascular disease: 130/80 mmHg; others: 140/90 mmHg.

Time frame:
26 weeks
Reported as:
Number · Participants
Number of 'Early Responder' Patients Who Achieve Individualized Blood Pressure Control After 1 or 2 Adjustments
ParticipantsUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Male patients with a target of <125/75 mmHg336
Male patients with a target of <130/80 mmHg271434
Male patients with a target of <140/90 mmHg312248
Female patients with a target of <125/75 mmHg222
Female patients with a target of <130/80 mmHg16534
Female patients with a target of <140/90 mmHg181142
SecondaryChange in the EQ-5D Score

The EQ-5D total indexed score (AUS) measures self-reported quality of life with the following 5 dimensions: mobility (range 1,2,3), self-care (range 1,2,3), usual activity (range 1,2,3), pain/discomfort (range 1,2,3) and anxiety/depression (range 1,2,3), where a 1 indicates no problems, a 2 indicates moderate problems, and a 3 indicates severe problems. The range of possible utility scores are between -0.217 (derived from worse responses from all 5 dimensions with severe problems ie 3,3,3,3,3) and 1.000 (no problems for all 5 dimensions) for each dimension. An increase in EQ-5D indexed score (AUS) indicates improvement.

Time frame:
Baseline and 26 weeks
Reported as:
Mean · change in EQ-5D score
Change in the EQ-5D Score
change in EQ-5D scoreUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Change in the EQ-5D Score-0.007 (-0.022 to 0.008)0.017 (-0.001 to 0.036)0.011 (-0.003 to 0.024)
SecondaryNumber of Patients With Depression

Patients with depression refers to potential depressive symptoms, not clinically diagnosed depression. The 2 question Arrol screening tool was used to determine if the patient had potential depressive symptoms. The 2 questions are: During the last month have you often been bothered by feeling down, depressed or hopeless? During the past month have you often been bothered by little interest or pleasure in doing things? The presence of potential depressive symptoms was determined by a 'yes' answer to either of these questions.

Time frame:
Baseline and week 26
Reported as:
Number · participants
Number of Patients With Depression
participantsUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Baseline15496185
Week 2612978151
SecondaryChange in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26

The CES-D score was from 0 to 30, with a higher score indicating a higher level of depression. The categories for the score are: 0 to 9 suggests no depression; 10 to 15 suggests mild depression; 16 to 24 suggests moderate depression; 24 or above suggests severe depression.

Time frame:
Baseline and week 26
Reported as:
Mean · change in CES-D score
Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26
change in CES-D scoreUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 261.03 ± 9.24-1.12 ± 10.951.19 ± 11.09
SecondaryParticipants With End Organ Disease at Baseline and Week 26

A patient was considered to have end organ damage with either of the following: 1) proteinuria (dipstick = 1+ or more or protein/creatinine ratio \> 30mg/mol or 24h urine protein \> 0.3g); 2) no proteinuria, but presence of microalbuminuria (urine albumin/creatinine ratio 3.6 to 25mg/mol(male) or 3.6 to 35mg/mol (female) detected; 3) no proteinuria or microalbuminuria, but presence of macroalbuminuria (urine albumin/creatinine ratio \> 25mg/mol(male) or \>35mg/mol (female) detected OR 4) ECG evidence of LVH (Sokolow-Lyon voltage criteria values \>= 38mm). Baseline potential for end organ damage was calculated in all 1562 randomised patients based on the criteria outlined above. If no investigation/data available, assumed no end-organ damage. It is important to note that given the limited number of ECGs at 26 weeks, between group comparisons should be limited to the two time points (baseline and 26 weeks).

Time frame:
Baseline and week 26
Reported as:
Number · participants
Participants With End Organ Disease at Baseline and Week 26
participantsUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Baseline226146315
Week 26 (N = 433, 277, 536)15788177
SecondaryChange in Self-care Behavior Score From Baseline to Week 26

A modified self-care behavior tool (questionnaire) was used to calculate 2 domain scales: maintenance and confidence. Each domain has a standardized score between 0 and 100. Self-care is best represented by maintenance. Confidence is an important process that moderates the relationship between self-care and outcomes. Higher index score suggests better self-care. A score of 70 or greater can be used as the cut-point to judge self-care adequacy.

Time frame:
Baseline and week 26
Reported as:
Mean · Change in score
Change in Self-care Behavior Score From Baseline to Week 26
Change in scoreUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Maintenance score2.59 ± 13.562.27 ± 12.563.17 ± 12.38
Confidence score (N = 422, 269, 520)0.93 ± 21.04-0.72 ± 20.04-0.71 ± 20.16
SecondaryRate of Treatment Compliance

The rate of compliance was planned to be estimated from the quantity of unused medication returned at each scheduled visit over the entire follow-up period. Rate of compliance = (tablets supplied - tablets returned)/(tablets for 100% compliance).

Time frame:
26 weeks

No measurements were reported for this outcome.

SecondaryNumber of Patients With Major Clinical Endpoints

Major clinical endpoints measured were all-cause mortality and fatal and non-fatal cardiovascular events (e.g. acute myocardial infarction, stroke and heart failure).

Time frame:
26 weeks
Reported as:
Number · participants
Number of Patients With Major Clinical Endpoints
participantsUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
All-cause mortality010
Non-fatal cardiovascular events15613

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-randomization—27/2,185 (1.2%)95/2,185 (4.3%)
Usual Care—24/524 (4.6%)47/524 (9%)
Monotherapy (Initial Monotherapy Arm)—15/360 (4.2%)36/360 (10%)
Combination (Initial Combination Therapy Arm)—22/678 (3.2%)105/678 (15.5%)
Most frequent serious events
Showing 10 of 88
Most frequent serious events
EventPre-randomizationUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Chest painCardiac disorders2/21851/5241/3605/678
DyspnoeaCardiac disorders0/21853/5241/3604/678
Angina pectorisCardiac disorders1/21853/5241/3600/678
AsthmaRespiratory, thoracic and mediastinal disorders0/21850/5242/3600/678
Chest discomfortCardiac disorders0/21852/5240/3600/678
SyncopeCardiac disorders1/21852/5240/3600/678
Productive coughRespiratory, thoracic and mediastinal disorders0/21852/5240/3600/678
Oedema peripheralGeneral disorders0/21850/5240/3602/678
Acute myocardial infarctionCardiac disorders1/21851/5241/3600/678
Angina unstableCardiac disorders0/21850/5241/3600/678
Most frequent other events
Most frequent other events
EventPre-randomizationUsual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)
Oedema peripheralGeneral disorders20/218527/5249/36067/678
DizzinessCardiac disorders77/218523/52428/36042/678

Baseline characteristics

Age Continuous
Age Continuous(years)Usual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)Total
Mean59 ± 1259 ± 1259 ± 1259 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Usual CareMonotherapy (Initial Monotherapy Arm)Combination (Initial Combination Therapy Arm)Total
Female201138260599
Male323222418963
08

Study locations

3 sites
  • Novartis Pharmaceuticals
    East Hanover, New Jersey 07936, United States
  • Professor Garry Jennings-Co Principal Investigator
    Melbourne, Australia
  • Professor Simon Stewart-Principal Investigator
    Melbourne, Australia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2009
First posted
May 15, 2009
Start
Jul 2009
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Aug 30, 2012
Last update
Dec 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00902304
Collaborators
Baker Heart and Diabetes Institute
Responsible party
Sponsor
First posted
May 15, 2009
Start date
Jul 2009
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Aug 30, 2012
Last update
Dec 4, 2012

Study contacts

Study Director
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine · Hydrochlorothiazide

Start the discussion